Signaling Pathways Targeting Colorectal Cancer in Egypt

Plain-language summary

This study investigates signaling pathways in colorectal cancer patients in Egypt by examining markers such as TIGAR, TRIM59, P53, AKT and GSH in tissue samples. Patients with histologically confirmed early-stage colorectal cancer, as well as at-risk patients (including those with ulcerative colitis, Crohn's disease or familial adenomatous polyposis), may take part. It was run as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Assiut University

Intervention

Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)

Start date

3/1/2018

Estimated completion

4/1/2020

Countries

Egypt

Related genes

Locations

• Asyut, Egypt

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* All Patients confirmed histopathologically to have early stages of colorectal cancer.
* Risky group patients (including those with ulcerative colitis, chron's disease, familial adenomatous polyposis).

Exclusion Criteria:

* Patients with previous history of CRC treated with chemotherapy or presence of other types of cancer.